Citations (110)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Eva Ayet, Sandra Yeste, Raquel F. Reinoso, María José Pretel, Ariadna Balada & Maria Teresa Serafini. (2021) Preliminary in vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual µ-opioid receptor partial agonist and σ1 receptor antagonist. Xenobiotica 51:5, pages 501-512.
Read now
Read now
Haruka Nishimuta, Kimihiko Sato, Takao Watanabe & Masashi Yabuki. (2019) Time-dependent inhibition (TDI) of CYP1A2 by a CYP3A4-mediated reactive metabolite: proposal for a novel mechanism of irreversible TDI by a non-suicide substrate. Xenobiotica 49:6, pages 636-645.
Read now
Read now
Robert J Riley & Claire E Wilson. (2015) Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. Expert Opinion on Drug Metabolism & Toxicology 11:4, pages 557-572.
Read now
Read now
Han Kiat Ho, James Chun Yip Chan, Klarissa D. Hardy & Eric Chun Yong Chan. (2015) Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metabolism Reviews 47:1, pages 21-28.
Read now
Read now
David M Stresser, Jialin Mao, Jane R Kenny, Barry C Jones & Kenneth Grime. (2014) Exploring concepts of in vitro time-dependent CYP inhibition assays. Expert Opinion on Drug Metabolism & Toxicology 10:2, pages 157-174.
Read now
Read now
Peter Ballard, Patrick Brassil, Khanh H. Bui, Hugues Dolgos, Carl Petersson, Anders Tunek & Peter J. H. Webborn. (2012) The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metabolism Reviews 44:3, pages 224-252.
Read now
Read now
Howard J. Burt, Aleksandra Galetin & J. Brian Houston. (2010) IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 40:5, pages 331-343.
Read now
Read now
Zhi-Wei Zhou & Shu-Feng Zhou. (2009) Application of mechanism-based CYP inhibition for predicting drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology 5:6, pages 579-605.
Read now
Read now
Masoud Jamei, Steve Marciniak, Kairui Feng, Adrian Barnett, Geoffrey Tucker & Amin Rostami-Hodjegan. (2009) The Simcyp® Population-based ADME Simulator. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 211-223.
Read now
Read now
Ping Zhao. (2008) The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. Expert Opinion on Drug Metabolism & Toxicology 4:2, pages 151-164.
Read now
Read now
K. Venkatakrishnan, R. S. Obach & A. Rostami-Hodjegan. (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment. Xenobiotica 37:10-11, pages 1225-1256.
Read now
Read now
N. J. Hewitt, E. L. Lecluyse & S. S. Ferguson. (2007) Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and correlations. Xenobiotica 37:10-11, pages 1196-1224.
Read now
Read now
Articles from other publishers (98)
Xiang Chen, Luyao Han, Yulin Zhao, Haoyan Huang, He Pan, Chenmeng Zhang, Huili Chen, Shanliang Sun, Sihui Yao, Xijing Chen & Yongjie Zhang. (2023) Mechanistic Study of Icaritin-Induced Inactivation of Cytochrome P450 2C9. Drug Metabolism and Disposition 51:6, pages 771-781.
Crossref
Crossref
Stefano Fontana, Simone Braggio, Mauro Corsi, Rob Riley, Chris Strock, Jenifer Bradley, Caterina Virginio & Paul Walker. 2023. The Handbook of Medicinal Chemistry. The Handbook of Medicinal Chemistry
533
596
.
Zhiheng Wang, Kuilong Zhou, Zhijie Liang, Huiting Zhang, Yangjie Song, Xiaomin Yang, Dongguo Xiang & Qingfan Xie. (2022) In Vitro Investigation on the Effect of Dendrobine on the Activity of Cytochrome P450 Enzymes. Planta Medica 89:01, pages 72-78.
Crossref
Crossref
DAN A. ROCK & LARRY C. WIENKERS. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
465
526
.
Zoey M. Bourgeois, Jordan Comfort, Matthew Schultz, Jonathan K. Challis, Jenna Cantin, Xiaowen Ji, John P. Giesy & Markus Brinkmann. (2022)
Predicting Hepatic Clearance of Psychotropic Drugs in Isolated Perfused Fish Livers Using a Combination of Two
In Vitro
Assays
. Environmental Science & Technology 56:22, pages 15839-15847.
Crossref
Crossref
Jian Zhao, Shimiao Wang, Sun Hee Kim, Sangdon Han, Elizabeth Rico-Bautista, Emmanuel Sturchler, Julie Nguyen, Hannah Tan, Christine Staley, Ana Karin Kusnetzow, Stephen F. Betz, Michael Johns, Lance Goulet, Rosa Luo, Melissa Fowler, Jon Athanacio, Stacy Markison, R. Scott Struthers & Yunfei Zhu. (2022) Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism. Bioorganic & Medicinal Chemistry Letters 71, pages 128807.
Crossref
Crossref
Sharoen Yu Ming Lim, Mustafa Ahmed Alshagga, Mohammed Abdullah Alshawsh, Chin Eng Ong & Yan Pan. (2022)
In vitro
effects of 95% khat ethanol extract (KEE) on human recombinant cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2 and CYP3A5
. Drug Metabolism and Personalized Therapy 37:1, pages 55-67.
Crossref
Crossref
Mariane Daou, Nancy A. Elnaker, Michael A. Ochsenkühn, Shady A. Amin, Ahmed F. Yousef & Lina F. Yousef. (2022) In vitro α-glucosidase inhibitory activity of Tamarix nilotica shoot extracts and fractions. PLOS ONE 17:3, pages e0264969.
Crossref
Crossref
L. Ward, Philip Butler & Robert J. Riley. 2022. The ADME Encyclopedia. The ADME Encyclopedia
631
641
.
Philip Butler & Robert J. Riley. 2022. The ADME Encyclopedia. The ADME Encyclopedia
448
456
.
Siva Nageswara Rao Gajula, Megha Sajakumar Pillai, Gananadhamu Samanthula & Rajesh Sonti. (2021) Cytochrome P450 enzymes: a review on drug metabolizing enzyme inhibition studies in drug discovery and development. Bioanalysis 13:17, pages 1355-1378.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
51
63
.
Huikai Sun, Holger Monenschein, Hans H. Schiffer, Holly A. Reichard, Shota Kikuchi, Maria Hopkins, Todd K. Macklin, Stephen Hitchcock, Mark Adams, Jason Green, Jason Brown, Sean T. Murphy, Nidhi Kaushal, Deanna R. Collia, Steve Moore, William J. Ray, Nicole Marion English, Mark Beresford Lewis CarltonNicola L. Brice. (2021) First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. Journal of Medicinal Chemistry 64:14, pages 9875-9890.
Crossref
Crossref
Jiangnan Dong, Su Li & Guangxuan Liu. (2021) Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2. Chemical Research in Toxicology 34:4, pages 1169-1174.
Crossref
Crossref
Pramod C. Nair, Tina B. Gillani, Tristan Rawling & Michael Murray. (2021) Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chemico-Biological Interactions 338, pages 109401.
Crossref
Crossref
Claire McWhirter. 2021. The Design of Covalent-Based Inhibitors. The Design of Covalent-Based Inhibitors
1
31
.
L. Ward, P. Butler & R. Riley. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
11
.
Philip Butler & Robert J. Riley. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
9
.
Yu Wang, Lili Xie & Jing Ni. 2021. Cytochrome P450. Cytochrome P450
121
139
.
Julie Huang. 2021. Cytochrome P450. Cytochrome P450
107
119
.
Yutao Liu, Chang Liu, Yamei Liu, Quanli Ge & Chen Sun. (2020)
Cytochrome P450 Mediated Bioactivation of Rutaevin, a Bioactive and Potentially Hepatotoxic Component of
Evodia Rutaecarpa
. Chemical Research in Toxicology 33:12, pages 3054-3064.
Crossref
Crossref
Rebeca Santes-Palacios, Sitlali Olguín-Reyes, Sandra Luz Hernández-Ojeda, Rafael Camacho-Carranza & Jesús Javier Espinosa-Aguirre. (2020) Differential inhibition of naringenin on human and rat cytochrome P450 2E1 activity. Toxicology in Vitro 69, pages 105009.
Crossref
Crossref
Giovanni Pellegrini, Dominic Paul Williams, Daniele AmadioBrian Kevin Park & Anja Kipar. (2020) Morphological and Mechanistic Aspects of Thiourea-Induced Acute Lung Injury and Tolerance in the Rat. Toxicologic Pathology 48:6, pages 725-737.
Crossref
Crossref
Mika Kosaka, Donglu Zhang, Simon Wong & Zhengyin Yan. (2020) NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition. Drug Metabolism and Disposition 48:8, pages 655-661.
Crossref
Crossref
Chuang Lu & Li Di. (2020)
In vitro
and
in vivo
methods to assess pharmacokinetic drug– drug interactions in drug discovery and development
. Biopharmaceutics & Drug Disposition 41:1-2, pages 3-31.
Crossref
Crossref
Florence I. Raynaud. 2020. Metabolomics for Biomedical Research. Metabolomics for Biomedical Research
159
199
.
Junho Jeon & Juliane Hollender. (2019) In vitro biotransformation of pharmaceuticals and pesticides by trout liver S9 in the presence and absence of carbamazepine. Ecotoxicology and Environmental Safety 183, pages 109513.
Crossref
Crossref
Bin Xie, Yuan-Yuan Lu, Zhuo-Hui Luo, Zhao Qu, Chun-Ge Zheng, Xin-An Huang, Hong-Yan Zhou, Ying-Jie Hu & Xiao-Ling Shen. (2019) Tenacigenin B ester derivatives from Marsdenia tenacissima actively inhibited CYP3A4 and enhanced in vivo antitumor activity of paclitaxel. Journal of Ethnopharmacology 235, pages 309-319.
Crossref
Crossref
J. Gerry Kenna & Jack Uetrecht. (2018) Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?. Drug Metabolism and Disposition 46:11, pages 1658-1669.
Crossref
Crossref
John T. Rodgers, Nadezhda Y. Davydova, Erickson M. Paragas, Jeffrey P. Jones & Dmitri R. Davydov. (2018) Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation. Biochemical Pharmacology 156, pages 86-98.
Crossref
Crossref
Prashant JoshiVinay R. Sonawane, Ibidapo S. Williams, Glen J. P. McCann, Linda Gatchie, Rajni Sharma, Naresh Satti, Bhabatosh Chaudhuri & Sandip B. Bharate. (2018)
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
via
screening of a natural product repository
. MedChemComm 9:2, pages 371-382.
Crossref
Crossref
Kristyna Krasulova, Ondrej Holas & Pavel Anzenbacher. (2017) Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Molecules 22:11, pages 1879.
Crossref
Crossref
Shaheed Rehman, In Kim, Min Choi, Seung Kim, Yonghui Zhang & Hye Yoo. (2017) Time-dependent Inhibition of CYP2C8 and CYP2C19 by Hedera helix Extracts, A Traditional Respiratory Herbal Medicine. Molecules 22:7, pages 1241.
Crossref
Crossref
Marzia Del Re, Stefano Fogli, Lisa Derosa, Francesco Massari, Paul De Souza, Stefania Crucitta, Sergio Bracarda, Daniele Santini & Romano Danesi. (2017) The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews 55, pages 71-82.
Crossref
Crossref
Nicholas Thomford, Kevin Dzobo, Denis Chopera, Ambroise Wonkam, Alfred Maroyi, Dee Blackhurst & Collet Dandara. (2016) In Vitro Reversible and Time-Dependent CYP450 Inhibition Profiles of Medicinal Herbal Plant Extracts Newbouldia laevis and Cassia abbreviata: Implications for Herb-Drug Interactions. Molecules 21:7, pages 891.
Crossref
Crossref
Johan Kajanus, Ingemar Jacobson, Annika Åstrand, Roine I. Olsson, Ulrik Gran, Annika Björe, Ola Fjellström, Öjvind Davidsson, Hans Emtenäs, Anders Dahlén, Boel Löfberg, Zhong-Qing Yuan, Johan Sundell, Johan Cassel, Jonna Gyll, Tommy Iliefski, Ågot Högberg, Emma Lindhardt & Jesper Malmberg. (2016) Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach. Bioorganic & Medicinal Chemistry Letters 26:8, pages 2023-2029.
Crossref
Crossref
Matthew A. Schiffler, Stephen Antonysamy, Shobha N. Bhattachar, Kristina M. Campanale, Srinivasan Chandrasekhar, Bradley Condon, Prashant V. Desai, Matthew J. Fisher, Christopher Groshong, Anita Harvey, Michael J. Hickey, Norman E. Hughes, Scott A. Jones, Euibong J. Kim, Steven L. Kuklish, John G. Luz, Bryan H. Norman, Richard E. Rathmell, John R. Rizzo, Thomas W. Seng, Stefan J. Thibodeaux, Timothy A. Woods, Jeremy S. York & Xiao-Peng Yu. (2015) Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors. Journal of Medicinal Chemistry 59:1, pages 194-205.
Crossref
Crossref
Dominik Dahlinger, Sabrina Duechting, Daniela Nuecken, Konrad Sydow, Uwe Fuhr & Sebastian Frechen. (2016) Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition. Journal of Pharmacological and Toxicological Methods 77, pages 66-75.
Crossref
Crossref
Shalu Jhajra & Saranjit Singh. (2016) Identification of stable and reactive metabolite(s) of nelfinavir in human liver microsomes and rCYP3A4. Journal of Pharmaceutical and Biomedical Analysis 118, pages 214-227.
Crossref
Crossref
Patrick Barton & Robert J. Riley. (2016) A new paradigm for navigating compound property related drug attrition. Drug Discovery Today 21:1, pages 72-81.
Crossref
Crossref
Xiaojing Wang, Minghua Sun, Connie New, Spencer Nam, Wesley P. Blackaby, Alastair J. Hodges, David Nash, Mizio Matteucci, Joseph P. Lyssikatos, Peter W. Fan, Suzanne Tay & Jae H. Chang. (2015) Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System. ACS Medicinal Chemistry Letters 6:8, pages 925-929.
Crossref
Crossref
Shigeki Kunikawa, Akira Tanaka, Koichiro Mukoyoshi, Shinya Nagashima, Hiroaki Tominaga, Noboru Chida, Mamoru Tasaki & Fumiyuki Shirai. (2015) Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug–drug interactions and P-gp liability. Bioorganic & Medicinal Chemistry 23:13, pages 3269-3277.
Crossref
Crossref
Liping Ma, Yahong Qin, Zhuowei Shen, Haihong Hu, Hui Zhou, Lushan Yu, Huidi Jiang & Su Zeng. (2015) Time-Dependent Inhibition of hOAT1 and hOAT3 by Anthraquinones. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 38:7, pages 992-995.
Crossref
Crossref
Thomas A. Dineen, Kui Chen, Alan C. Cheng, Katayoun Derakhchan, Oleg Epstein, Joel Esmay, Dean Hickman, Chuck E. Kreiman, Isaac E. Marx, Robert C. Wahl, Paul H. Wen, Matthew M. Weiss, Douglas A. Whittington, Stephen Wood, Robert T. FremeauJr.Jr., Ryan D. White & Vinod F. Patel. (2014)
Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (
S
)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′
H
-spiro[chromeno[2,3-
b
]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)
. Journal of Medicinal Chemistry 57:23, pages 9811-9831.
Crossref
Crossref
Vamshi K. Manda, Olivia R. Dale, Charles Awortwe, Zulfiqar Ali, Ikhlas A. Khan, Larry A. Walker & Shabana I. Khan. (2014) Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. Frontiers in Pharmacology 5.
Crossref
Crossref
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET
353
396
.
Paul M. Scola, Li-Qiang Sun, Alan Xiangdong Wang, Jie Chen, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M. Bilder, Stanley V. D’Andrea, Barbara Zheng, Piyasena Hewawasam, Yong Tu, Jacques Friborg, Paul Falk, Dennis Hernandez, Steven Levine, Chaoqun Chen, Fei Yu, Amy K. Sheaffer, Guangzhi Zhai, Diana Barry, Jay O. Knipe, Yong-Hae Han, Richard Schartman, Maria Donoso, Kathy Mosure, Michael W. Sinz, Tatyana Zvyaga, Andrew C. Good, Ramkumar Rajamani, Kevin Kish, Jeffrey Tredup, Herbert E. Klei, Qi Gao, Luciano Mueller, Richard J. Colonno, Dennis M. Grasela, Stephen P. Adams, James Loy, Paul C. Levesque, Huabin Sun, Hong Shi, Lucy Sun, William Warner, Danshi Li, Jialong Zhu, Nicholas A. Meanwell & Fiona McPhee. (2014) The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry 57:5, pages 1730-1752.
Crossref
Crossref
Masoud Jamei, Karen Yeo & Amin Rostami-Hodjegan. 2014. Handbook of Personalized Medicine. Handbook of Personalized Medicine
685
726
.
Kazumasa Kozakai, Yasuhiro Yamada, Motoji Oshikata, Taiji Kawase, Etsuko Suzuki, Yukari Haramaki & Hideki Taniguchi. (2014) Cocktail-substrate Approach-based High-throughput Assay for Evaluation of Direct and Time-dependent Inhibition of Multiple Cytochrome P450 Isoforms. Drug Metabolism and Pharmacokinetics 29:2, pages 198-207.
Crossref
Crossref
Gary W. Caldwell & Zhengyin Yan. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
315
336
.
Gary W. Caldwell & Zhengyin Yan. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
281
303
.
Yuan Chen & Adrian J. Fretland. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
269
279
.
Ryan C. Schoenfeld, David L. Bourdet, Ken A. Brameld, Elbert Chin, Javier de Vicente, Amy Fung, Seth F. Harris, Eun K. Lee, Sophie Le Pogam, Vincent Leveque, Jim Li, Alfred S.-T. Lui, Isabel Najera, Sonal Rajyaguru, Michael Sangi, Sandra Steiner, Francisco X. Talamas, Joshua P. Taygerly & Junping Zhao. (2013) Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B. Journal of Medicinal Chemistry 56:20, pages 8163-8182.
Crossref
Crossref
Tonika Bohnert & Lawrence L. Gan. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
61
.
Andrew V. Stachulski, Thomas A. Baillie, B. Kevin Park, R. Scott Obach, Deepak K. Dalvie, Dominic P. Williams, Abhishek Srivastava, Sophie L. Regan, Daniel J. Antoine, Christopher E. P. Goldring, Alvin J. L. Chia, Neil R. Kitteringham, Laura E. Randle, Hayley Callan, J. Luis Castrejon, John Farrell, Dean J. Naisbitt & Martin S. Lennard. (2013) The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews 33:5, pages 985-1080.
Crossref
Crossref
Chris De Savi, David Waterson, Andrew Pape, Scott Lamont, Elma Hadley, Mark Mills, Ken M. Page, Jonathan Bowyer & Rose A. Maciewicz. (2013) Hydantoin based inhibitors of MMP13—Discovery of AZD6605. Bioorganic & Medicinal Chemistry Letters 23:16, pages 4705-4712.
Crossref
Crossref
P Ballard, P Brassil, K H Bui, H Dolgos, C Petersson, A Tunek & P J H Webborn. 2013. Drug Discovery and Development. Drug Discovery and Development
135
155
.
P Beswick & A Naylor. 2013. Drug Discovery and Development. Drug Discovery and Development
119
134
.
Cynthia Palmer, Mason Pairish, Susan Kephart, Djamal Bouzida, Jingrong Cui, Judith Deal, Liming Dong, Danlin Gu, Angelica Linton, Indrawan McAlpine, Shinji Yamazaki, Evan Smith, Annette John-Baptiste, Shubha Bagrodia, Robert Kania & Chuangxing Guo. (2012) Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug–drug interaction. Bioorganic & Medicinal Chemistry Letters 22:24, pages 7605-7609.
Crossref
Crossref
Jane R. Kenny, Sophie Mukadam, Chenghong Zhang, Suzanne Tay, Carol Collins, Aleksandra Galetin & S. Cyrus Khojasteh. (2012) Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction. Pharmaceutical Research 29:7, pages 1960-1976.
Crossref
Crossref
Brian S. Safina, Stewart Baker, Matt Baumgardner, Paul M. Blaney, Bryan K. Chan, Yung-Hsiang Chen, Matthew W. Cartwright, Georgette Castanedo, Christine Chabot, Arnaud J. Cheguillaume, Paul Goldsmith, David M. Goldstein, Bindu Goyal, Timothy Hancox, Raj K. Handa, Pravin S Iyer, Jasmit Kaur, Rama Kondru, Jane R. Kenny, Sussie L. Krintel, Jun Li, John Lesnick, Matthew C. Lucas, Cristina Lewis, Sophie Mukadam, Jeremy Murray, Alan J. Nadin, Jim Nonomiya, Fernando Padilla, Wylie S. Palmer, Jodie Pang, Neil Pegg, Steve Price, Karin Reif, Laurent Salphati, Pascal A. Savy, Eileen M. Seward, Stephen Shuttleworth, Sukhjit Sohal, Zachary K. Sweeney, Suzanne Tay, Parcharee Tivitmahaisoon, Bohdan Waszkowycz, Binqing Wei, Qin Yue, Chenghong Zhang & Daniel P. Sutherlin. (2012) Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition. Journal of Medicinal Chemistry 55:12, pages 5887-5900.
Crossref
Crossref
Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Lee C. Preusser, James S. Polakowski, Kent D. Stewart, Chris Tse, Steven K. Davidsen & Michael R. Michaelides. (2012) Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorganic & Medicinal Chemistry Letters 22:9, pages 3208-3212.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
183
207
.
Alexander V. LyubimovDeepak K. Dalvie & Cho‐Ming Loi. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Alexander V. LyubimovJames M. MKim. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
28
.
Alexander V. LyubimovDeepak K. Dalvie. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
54
.
Kaisa A. Salminen, Achim Meyer, Peter Imming & Hannu Raunio. (2011) CYP2C19 Progress Curve Analysis and Mechanism-Based Inactivation by Three Methylenedioxyphenyl Compounds. Drug Metabolism and Disposition 39:12, pages 2283-2289.
Crossref
Crossref
Moa Andresen Bergström, Emre M. Isin, Neal CastagnoliJr.Jr. & Claire E. Milne. (2011) Bioactivation Pathways of the Cannabinoid Receptor 1 Antagonist Rimonabant. Drug Metabolism and Disposition 39:10, pages 1823-1832.
Crossref
Crossref
Shintaro Nakayama, Hideo Takakusa, Akiko Watanabe, Yoshihiro Miyaji, Wataru Suzuki, Daisuke Sugiyama, Kazuhito Shiosakai, Kokichi Honda, Noriko Okudaira, Takashi Izumi & Osamu Okazaki. (2011) Combination of GSH Trapping and Time-Dependent Inhibition Assays as a Predictive Method of Drugs Generating Highly Reactive Metabolites. Drug Metabolism and Disposition 39:7, pages 1247-1254.
Crossref
Crossref
Kaisa A. Salminen, Jukka Leppänen, Jarkko I. Venäläinen, Markku Pasanen, Seppo Auriola, Risto O. Juvonen & Hannu Raunio. (2011) Simple, Direct, and Informative Method for the Assessment of CYP2C19 Enzyme Inactivation Kinetics. Drug Metabolism and Disposition 39:3, pages 412-418.
Crossref
Crossref
Youngshin Kwak, Gary Coppola, Cornelia J. Forster, Thomas A. Gilmore, Yongjin Gong, Aaron Kanter, Alan Neubert, Bryan Stroup, Paul Szklennik, Susanne Glowienke, Pascal Stadelmann, Leslie Bell, Shari Bickford, Eric Gangl, Mithat Gunduz, Monish Jain, Jenny Zhan & Michael H. Serrano-Wu. (2011) A new structural alert for benzimidazoles: 2,6-Dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk. Bioorganic & Medicinal Chemistry Letters 21:5, pages 1422-1424.
Crossref
Crossref
Daniel Simard, Yves Leblanc, Carl Berthelette, M. Helmi Zaghdane, Carmela Molinaro, Zhaoyin Wang, Michel Gallant, Stephen Lau, Trinh Thao, Martine Hamel, Rino Stocco, Nicole Sawyer, Susan Sillaots, Francois Gervais, Robert Houle & Jean-François Lévesque. (2011) Azaindoles as potent CRTH2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 21:2, pages 841-845.
Crossref
Crossref
Graham F. Smith. 2011. Progress in Medicinal Chemistry Volume 50. Progress in Medicinal Chemistry Volume 50
1
47
.
Anh P. Truong, Gergley Tóth, Gary D. Probst, Jennifer M. Sealy, Simeon Bowers, David W.G. Wone, Darren Dressen, Roy K. Hom, Andrei W. Konradi, Hing L. Sham, Jing Wu, Brian T. Peterson, Lany Ruslim, Michael P. Bova, Dora Kholodenko, Ruth N. Motter, Frédérique Bard, Pamela Santiago, Huifang Ni, David Chian, Ferdie Soriano, Tracy Cole, Elizabeth F. Brigham, Karina Wong, Wes Zmolek, Erich Goldbach, Bhushan Samant, Linda Chen, Hongbing Zhang, David F. Nakamura, Kevin P. Quinn, Ted A. Yednock & John-Michael Sauer. (2010) Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorganic & Medicinal Chemistry Letters 20:21, pages 6231-6236.
Crossref
Crossref
Simon G. Wong, Peter W. Fan, Raju Subramanian, George R. Tonn, Kirk R. Henne, Michael G. Johnson, Michelle Tadano Lohr & Bradley K. Wong. (2010) Bioactivation of a Novel 2-Methylindole-Containing Dual Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type-2 Cells/d-Prostanoid Receptor Antagonist Leads to Mechanism-Based CYP3A Inactivation: Glutathione Adduct Characterization and Prediction of In Vivo Drug-Drug Interaction. Drug Metabolism and Disposition 38:5, pages 841-850.
Crossref
Crossref
Dan Rock & Larry C. Wienkers. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
56
.
Jane R. Kenny, Dermot F. McGinnity, Ken Grime & Robert J. Riley. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
38
.
Thomas M. Polasek, Janani S. Sadagopal, David J. Elliot & John O. Miners. (2009) In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. European Journal of Clinical Pharmacology 66:3, pages 275-283.
Crossref
Crossref
Thomas S. Reger, Jasmine Zunic, Nicholas Stock, Bowei Wang, Nicholas D. Smith, Benito Munoz, Mitchell D. Green, Michael F. Gardner, Joyce P. James, Weichao Chen, Kenneth Alves, Qian Si, Kelly M. Treonze, Russell B. Lingham & Richard A. Mumford. (2010) Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists. Bioorganic & Medicinal Chemistry Letters 20:3, pages 1173-1176.
Crossref
Crossref
J. Brian Houston & Aleksandra Galetin. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
169
215
.
R. Scott Obach, Odette A. Fahmi & Robert L. Walsky. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
473
495
.
Amin Rostami-Hodjegan. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
317
341
.
R. Scott Obach. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
241
264
.
Tonika Bohnert & Liang‐Shang Gan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
91
176
.
Amin Rostami‐Hodjegan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
549
568
.
Shinya Nagashima, Takeshi Hondo, Hiroshi Nagata, Takashi Ogiyama, Jun Maeda, Hiroaki Hoshii, Toru Kontani, Sadao Kuromitsu, Keiko Ohga, Masaya Orita, Kazuki Ohno, Ayako Moritomo, Koichi Shiozuka, Masako Furutani, Makoto Takeuchi, Mitsuaki Ohta & Shin-ichi Tsukamoto. (2009) Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorganic & Medicinal Chemistry 17:19, pages 6926-6936.
Crossref
Crossref
Ben-Fillippo Krippendorff, Roland Neuhaus, Philip Lienau, Andreas Reichel & Wilhelm Huisinga. (2009) Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values. SLAS Discovery 14:8, pages 913-923.
Crossref
Crossref
Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim & Michael Zientek. 2009. Hit and Lead Profiling. Hit and Lead Profiling
165
196
.
Odette A. Fahmi, Susan Hurst, David Plowchalk, Jack Cook, Feng Guo, Kuresh Youdim, Maurice Dickins, Alex Phipps, Amanda Darekar, Ruth Hyland & R. Scott Obach. (2009) Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction. Drug Metabolism and Disposition 37:8, pages 1658-1666.
Crossref
Crossref
Scott W. Grimm, Heidi J. Einolf, Steven D. Hall, Kan He, Heng-Keang Lim, Kah-Hiing John Ling, Chuang Lu, Amin A. Nomeir, Eleanore Seibert, Konstantine W. Skordos, George R. Tonn, Robert Van Horn, Regina W. Wang, Y. Nancy Wong, Tian J. Yang & R. Scott Obach. (2009) The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metabolism and Disposition 37:7, pages 1355-1370.
Crossref
Crossref
Linus S. Lin, Thomas LanzaJr.Jr., James P. Jewell, Ping Liu, Carrie Jones, Gerard R. Kieczykowski, Kelly Treonze, Qian Si, Salony Manior, Gloria Koo, Xinchun Tong, Junying Wang, Anne Schuelke, James Pivnichny, Regina Wang, Conrad Raab, Stella Vincent, Philip Davies, Malcolm MacCoss, Richard A. Mumford & William K. Hagmann. (2009)
Discovery of
N
-{
N
-[(3-Cyanophenyl)sulfonyl]-4(
R
)-cyclobutylamino-(
l
)-prolyl}-4-[(3′,5′-dichloroisonicotinoyl)amino]-(
l
)-phenylalanine (MK-0668), an Extremely Potent and Orally Active Antagonist of Very Late Antigen-4
. Journal of Medicinal Chemistry 52:11, pages 3449-3452.
Crossref
Crossref
Dan Rock & Larry C. Wienkers. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
479
534
.
Kenneth H. Grime, James Bird, Douglas Ferguson & Robert J. Riley. (2009) Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36:2-3, pages 175-191.
Crossref
Crossref
Masoud Jamei, Gemma L. Dickinson & Amin Rostami-Hodjegan. (2009) A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates. Drug Metabolism and Pharmacokinetics 24:1, pages 53-75.
Crossref
Crossref
J. Matthew Hutzler, Larissa M. Balogh, Michael Zientek, Vikas Kumar & Timothy S. Tracy. (2009) Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (±)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection. Drug Metabolism and Disposition 37:1, pages 59-65.
Crossref
Crossref
Barry C. Jones, Donald S. Middleton & Kuresh Youdim. 2009. Progress in Medicinal Chemistry Volume 47. Progress in Medicinal Chemistry Volume 47
239
263
.
Stephen Fowler & Hongjian Zhang. (2008) In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions. The AAPS Journal 10:2, pages 410-424.
Crossref
Crossref
Yue-Zhong Shu, Benjamin M. Johnson & Tian J. Yang. (2008) Role of Biotransformation Studies in Minimizing Metabolism-Related Liabilities in Drug Discovery. The AAPS Journal 10:1, pages 178-192.
Crossref
Crossref